BridgeBio Pharma (BBIO) Convertible Debt (2021 - 2022)

BridgeBio Pharma has reported Convertible Debt for 6 years, with the latest figure at $739.9 million in Q2 2025.

• Quarterly Convertible Debt rose 35.94% year-over-year to $739.9 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $739.9 million (up 35.94% YoY) and the FY2024 annual result came in at $738.9 million, up 35.98% from the prior year.
• Convertible Debt rose to $739.9 million in Q2 2025 per BBIO's latest filing, from $545.6 million in the prior quarter.
• Over five years, Convertible Debt peaked at $739.9 million in Q2 2025 and troughed at $539.5 million in Q3 2021.
• A 5-year average of $628.3 million and a median of $545.2 million in 2024 frame the typical range for Convertible Debt.
• The sharpest annual moves came in 2021 and 2022: Convertible Debt soared 98.35% in 2021, then declined 26.14% in 2022.
• Over 5 years, Convertible Debt stood at $733.1 million in 2021, then decreased by 26.12% to $541.6 million in 2022, then grew by 0.32% to $543.4 million in 2023, then soared by 35.98% to $738.9 million in 2024, then grew by 0.14% to $739.9 million in 2025.
• According to Business Quant data, Convertible Debt over the past three periods registered $739.9 million, $545.6 million, and $738.9 million for Q2 2025, Q1 2025, and Q4 2024 respectively.